Alexia Iasonos, PhD

Associate Attending Biostatistician
Pictured: Alexia Iasonos
Office Phone:
646-735-8115
Education:
University of Albany

Current Research Interests

Dr. Alexia Iasonos’ expertise is in the design and analysis of clinical trials, primarily dose finding Phase I trials that are model based, as well as predictive modeling in surgical outcomes. Her methodological research is focused on evaluating Bayesian adaptive Phase I designs, specifically the Continual Reassessment Method (CRM). She has compared CRM with the standard 3+3 dose escalation scheme [Abstract] as part of a 2-year award from the Experimental Therapeutic Center of Memorial Sloan Kettering to study dose finding algorithms. She has lead a team of programmers and data managers to create the infrastructure (software and a web interface) that facilitates clinical personnel in obtaining the dose allocation for CRM seamlessly. Her clinical collaborations focus on gynecologic malignancies. Her work with gynecologic oncologists and surgeons varies from exploring biomarkers to predicting survival outcomes. Most recently she has evaluated clinical endpoints for consolidation or maintenance trials given to patients in remission. 

Alexia has previously worked with QoL outcomes as part of collaboration with Health Outcomes (HOGR) where the group analyzed patient reported outcomes and compared these with clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events. She has also worked with the Urology group in developing predictive models and nomograms that can be used pre-operatively to enable a more informed clinical decision-making process. She has been a statistical reviewer for the institutional Data and Safety Monitoring Committee for Phase I-II trials since 2006.

She is currently the primary statistician for the Gynecology service, Developmental Therapeutic Center and Quality Control Initiative at Memorial Sloan Kettering. She is serving as a scientific reviewer on the institution’s Research Council and the ASCO Grants selection committee.

Publications by Alexia Iasonos

Iasonos A, Sabbatini P, Spriggs DR, Aghajanian CA, O'Cearbhaill RE, Hensley ML, Thaler HT. Identifying Clinical Improvement in Consolidation Single-arm Phase II Trials in Ovarian Cancer Patients in Second or Greater Clinical. International Journal of Gynecological Cancer 2011 Nov 11. [Epub ahead of print]. [PubMed Abstract]

Iasonos A, Zohar S, O'Quigley J. Incorporating lower grade toxicity information into dose finding designs. Clin Trials. 2011;8(4):370-9. [PubMed Abstract]

Iasonos A., Ostrovnaya I. Estimating the dose-toxicity curve in completed phase I studies. Statistics in Medicine 2011 Jul 30;30(17):2117-29. [PubMed Abstract]

Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials. 2008;5(5):465-77. [PubMed Abstract]

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008 Mar 10;26(8):1364-70. Review. [PubMed Abstract]